Neumora Therapeutics (NMRA) Expected to Announce Earnings on Monday

Neumora Therapeutics (NASDAQ:NMRA) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Neumora Therapeutics to post earnings of ($0.34) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Neumora Therapeutics Trading Down 1.7%

NASDAQ NMRA opened at $3.49 on Friday. The stock has a market cap of $583.14 million, a P/E ratio of -2.37 and a beta of 3.20. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $3.65. The stock has a 50 day simple moving average of $2.37 and a two-hundred day simple moving average of $2.14. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85.

Insider Buying and Selling at Neumora Therapeutics

In related news, insider Paul L. Berns sold 9,819 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the completion of the transaction, the insider directly owned 7,395,185 shares in the company, valued at $25,957,099.35. This trade represents a 0.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 23,387 shares of company stock valued at $82,647. 26.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Neumora Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of NMRA. Virtu Financial LLC purchased a new position in shares of Neumora Therapeutics in the 3rd quarter worth about $31,000. Fred Alger Management LLC purchased a new stake in Neumora Therapeutics during the 4th quarter valued at about $40,000. Canada Pension Plan Investment Board bought a new stake in Neumora Therapeutics during the 2nd quarter valued at about $41,000. Public Employees Retirement System of Ohio bought a new stake in Neumora Therapeutics during the 3rd quarter valued at about $44,000. Finally, Barclays PLC raised its holdings in Neumora Therapeutics by 202.0% in the fourth quarter. Barclays PLC now owns 30,924 shares of the company’s stock worth $55,000 after buying an additional 20,683 shares during the last quarter. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on NMRA shares. Mizuho set a $6.00 price target on Neumora Therapeutics in a research note on Monday, January 5th. Leerink Partners began coverage on shares of Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price objective for the company. William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their target price for the company from $4.00 to $7.00 in a research note on Monday, December 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.13.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.